Featured Research

from universities, journals, and other organizations

Three-way control of fetal heart-cell proliferation could help regenerate cardiac cells

Date:
October 11, 2010
Source:
University of Pennsylvania School of Medicine
Summary:
Heart muscle cells do not normally replicate in adult tissue, but multiply with abandoned during development. This is why the loss of heart muscle after a heart attack is so dire -- you can't grow enough new heart muscle to make up for the loss. Researchers describe the interconnections between three-molecules that control fetal, heart-muscle-cell proliferation in a mouse model that will help cardiologists better understand the natural repair process after heart attacks.

Thickened heart wall due to loss of Hdac2-Hopx function.
Credit: Jon Epstein, MD, University of Pennsylvania School of Medicine

Heart muscle cells do not normally replicate in adult tissue, but multiply with abandoned during development. This is why the loss of heart muscle after a heart attack is so dire -- you can't grow enough new heart muscle to make up for the loss.

A team of researchers at the University of Pennsylvania School of Medicine describe the interconnections between three-molecules that control fetal, heart-muscle-cell proliferation in a mouse model that will help cardiologists better understand the natural repair process after heart attacks and help scientists learn how to expand cardiac stem cells for regenerative therapies.

The research team, led by Jonathan Epstein, MD, chair of the Department of Cell and Developmental Biology, and Chinmay Trivedi, MD, PhD, an Instructor in the same department, report their findings in the cover article of the most recent issue of Developmental Cell.

The Penn team showed that an enzyme called Hdac2 directly modifies a protein called Gata4, and a third protein called Hopx, which appears to have adopted a new function. Hopx is a member of a family of ancient, evolutionally conserved proteins that normally bind DNA. In this case, however, rather than binding to DNA, it works to bring two other proteins, Hdac2 and Gata4, together. By performing this unexpected matchmaker function, Hopx helps to control the rate at which heart muscle cells divide.

"Although the degree to which hearts can repair themselves after injury is controversial, if there is a natural regeneration process, even if normally insufficient and modest, then approaches leveraging this insight this could be useful for boosting new growth so that it has a clinically significant effect," says Epstein "We are eager to see if drugs like Hdac inhibitors will have this effect."

The scientists found an unexpected function for Hdac2 as well. This enzyme normally acts as a switch that regulates how DNA is packaged inside the cell, and therefore how large groups of genes are turned on and off. Epstein said that his team was surprised discover that in the developing heart this packaging role was not the critical function.

"Rather, Hdac2 seems to be working directly on other proteins, and not on DNA structure, to control replication of heart muscle cells," he says.

Hdac inhibitors are already in trials for cancer and one, valproic acid, has been used for decades to treat seizures. These inhibitors are a new class of agents that inhibit the proliferation of tumor cells in culture. Hdac inhibitors that are used to fight T cell lymphoma could possibly be used to enhance cardiac cell proliferation, say after a heart attack, when growing new heart muscle to replace damaged tissue would be is most needed.

"This could help to explain why Hdac inhibitors improve outcomes after heart attacks in animal models," says Trivedi.

This research was funded by the National Heart, Lung and Blood Institute, the WW Smith Charitable Trust, and the American Heart Association.


Story Source:

The above story is based on materials provided by University of Pennsylvania School of Medicine. Note: Materials may be edited for content and length.


Journal Reference:

  1. Chinmay M. Trivedi, Wenting Zhu, Qiaohong Wang, Cheng Jia, Hae Jin Kee, Li Li, Sridhar Hannenhalli, Jonathan A. Epstein. Hopx and Hdac2 Interact to Modulate Gata4 Acetylation and Embryonic Cardiac Myocyte Proliferation. Developmental Cell, 2010; 19 (3): 450 DOI: 10.1016/j.devcel.2010.08.012

Cite This Page:

University of Pennsylvania School of Medicine. "Three-way control of fetal heart-cell proliferation could help regenerate cardiac cells." ScienceDaily. ScienceDaily, 11 October 2010. <www.sciencedaily.com/releases/2010/10/101007171409.htm>.
University of Pennsylvania School of Medicine. (2010, October 11). Three-way control of fetal heart-cell proliferation could help regenerate cardiac cells. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2010/10/101007171409.htm
University of Pennsylvania School of Medicine. "Three-way control of fetal heart-cell proliferation could help regenerate cardiac cells." ScienceDaily. www.sciencedaily.com/releases/2010/10/101007171409.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins